Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01738594 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01738594 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 7 participants.
The verdict
NCT01738594, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects and the best dose of carfilzomib when given together with or without romidepsin in treating patients with stage IA-IVB cutaneous T-cell lymphoma. Carfilzomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving carfilzomib alone is more effective than when given together with romidepsin.
Interventions
- OTHER laboratory biomarker analysis
- DRUG carfilzomib
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-03-22 |
| Est. Completion | 2016-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01738594
The ClinicalTrials.gov registry entry for NCT01738594 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01738594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01738594 about?
NCT01738594 is a clinical study titled "Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma". This randomized phase I trial studies the side effects and the best dose of carfilzomib when given together with or without romidepsin in treating patients with stage IA-IVB cutaneous T-cell lymphoma. Carfilzomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes need...
What is the current status of trial NCT01738594?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-03-22. Estimated completion is 2016-10-11.
What interventions are being tested in trial NCT01738594?
The interventions under investigation include: laboratory biomarker analysis (OTHER), carfilzomib (DRUG), romidepsin (DRUG).
Who is sponsoring clinical trial NCT01738594?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.